Human platelet acid extract obtained from both whole platelets and from isolated subcellular granules was partially purified by DEAE-cellulose chromatography and Sephadex gel filtration. The heat-stable, nondialyzable cationic protein fraction with a mol wt of approximately 30,000 produced a biphasic increase in vascular permeability in rabbit skin and also had antiheparin activity. The acute (15 min) increase in vascular permeability was blocked by prior treatment of the animal with antihistamine and was characterized histologically by edema of perivascular tissues and dilation of capillaries and veinules. The delayed (3 hr) permeability effect was not blocked by antihistamine and was characterized histologically by leukocytic infiltration into the skin. The experiments described suggest that human platelet lysosomal release of cationic proteins may increase vascular permeability by several mechanisms including endogenous histamine release as well as delayed chemotaxis.
A B S T R A C T Human platelet acid extract obtained from both whole platelets and from isolated subcellular granules was partially purified by DEAE-cellulose chromatography and Sephadex gel filtration. The heatstable, nondialyzable cationic protein fraction with a mol wt of approximately 30,000 produced a biphasic increase in vascular permeability in rabbit skin and also had antiheparin activity. The acute (15 min) increase in vascular permeability was blocked by prior treatment of the animal with antihistamine and was characterized histologically by edema of perivascular tissues and dilation of capillaries and veinules. The delayed (3 hr) permeability effect was not blocked by antihistamine and was characterized histologically by leukocytic infiltration into the skin. The experiments described suggest that human platelet lysosomal release of cationic proteins may increase vascular permeability by several mechanisms including endogenous histamine release as well as delayed chemotaxis. INTRODUCTION Recent studies suggest that platelets may contribute to the inflammatory response accompanying tissue injury by the release during such interactions of intracellular constituents which increase vascular permeability (1, 2) . We have previously demonstrated that a cationic protein extract obtained from human platelet granules increased vascular permeability in both mouse and rabbit skin presumably by inducing histamine release from tissue mast cells (3) . The cationic protein fraction itself did not contain histamine, serotonin, kallikrein, plasmin, C! or PF/dil. The present studies were undertaken to analyze in greater detail the cationic permeability protein(s) of human platelets. Human platelet acid extract was partially purified by DEAE-cellulose chromatograDr. Weksler held a U. S. Public Health Service Special Fellowship.
Received for publication 12 August 1971 and in revised form 15 October 1971. York Hospital-Cornell Medical phy and Sephadex (Pharmacia Fine Chemicals, Inc., Piscataway, N. J.) gel filtration. The heat-stable, nondialyzable platelet permeability factor with a mol wt of approximately 30,000 produced a biphasic permeability response in rabbits. The acute (15 min) permeability effect was blocked by prior treatment of the animal with antihistamine while the delayed (3 hr) permeability effect was not blocked by an antihistamine and was characterized by leukocytic infiltration into the skin.
METHODS

Preparation of platelet fractions
Human platelet concentrates prepared from 10-20 U of freshly collected whole blood in acid citrate dextrose anticoagulant were generously supplied by the New York Blood Center. The concentrates were processed within 24 hr of the day of collection. Platelets were separated as previously described (3) . Contamination of platelets by leukocytes in multiple samples was less than one cell per 10,000 platelets. The isolated platelets were washed (3) and extracted three times with 2 ml volumes of ice-cold 0.2 N H2S04.
The combined acid extracts were cleared by centrifugation at 12,000 g, pooled, neutralized by dropwise addition of 1.0 N NaOH and lyophilized. Before Histamine release from rabbit WBC and platelets WBC preparation. New Zealand white adult rabbits were injected intraperitoneally with 500 ml normal saline containing 0.15% oyster glycogen (Calbiochem, Los Angeles, Calif.). 15 hr later the rabbits were killed and the peritoneal fluid drained into 5 cc 0.25% EDTA saline.
Leukocytes were sedimented by centrifugation at 77 g for 5 min at room temperature and were washed three times in a Tris buffer ((5) and resuspended in the same buffer containing Ca++ 6 X 10' M and Mg++ 1 X 10' M, at a concentration of 9 X 106 polymorphonuclear leukocytes/ml. Platelet preparation. Arterial blood from rabbits was drawn by cannula (Medicut, A. S. Aloe Co., St. Louis, Mo.) into I'a volume 3.8% trisodium citrate and centrifuged at 100 g for 30 min at room temperature to yield platelet rich plasma (PRP). The platelet count was 800,000/mm3.
PRP was centrifuged at 225 g for 25 min at room temperature to sediment platelets. They were washed three times in Tyrode's solution lacking Ca or Mg and resuspended in Tyrode's solution containing 2 X 10-' M of Ca++ and Mg++ at a concentration of 855,000/mm3.
Samples of WBC suspension, PRP, and washed platelets (1.5-2 ml) were placed in siliconized glass tubes and saline or HPAE 100 to 200 ,ul/ml of cells was added. After gentle mixing, the tubes were incubated at 37'C with shaking on a Lab Tek (Ames Laboratories, Westmont, Ill.) aliquot mixer for 15 min and then centrifuged at 1000 g at room temperature for 5 min. Supernate (0.5 ml for platelets, 1 ml for WBC) was extracted for histamine according to the fluorimetric method of Shore, Burkhalter, and Cohn (6) as modified by Gocke and Osler (7) . Per cent histamine release was calculated from comparison with total histamine extracted from whole WBC or platelet suspensions.
Platelet factor 4 assay
Antiheparin activity (platelet factor 4) of the platelet fractions was measured using the thrombin time system of Poplawski and Niewiarowski (8) . The mixture included 0.3 ml human platelet poor plasma, 0.1 ml saline or test platelet extract, 0.1 ml heparin (0.3 U/ml). Ths ml of Parke, Davis (Parke, Davis & Co., Detroit, Mich.) bovine thrombin (10 U/ml) was added and the clotting time recorded with mixing at 37°C.
Separation of the acid extract on diethylaminoethyl-cellulose (DEAE)
The lyophilized acid extract was dissolved in 2 ml distilled water. This was centrifuged at 10,000 g at 4°C for 10 min. The small precipitate was washed with 1 ml water and once with 0.5 ml acetate buffer (0.01 M pH 4.0). The pooled supernate (3.5 ml) was applied by gravity to a Whatman DEAE-cellulose column (1 X 27.5 cm) equilibrated with phosphate buffer 0.01 M pH 8.0. After the first protein peak was eluted with the equilibrating buffer, a gradient of sodium chloride was established using 0.5 M NaCl in 0.01 M Na2HPO4 as the terminal buffer. The fractions collected were tested for vascular permeability-inducing activity in the skin of rabbits after adjustment to physiological pH and salt concentration.
Separation of the permeability-inducing factor(s) by gel filtration on a column of Sephadex G-75
The permeability-inducing protein fractions from the DEAE column were pooled, lyophilized, and redissolved in 2 ml distilled water. The fraction was dialyzed over 90 min against 4 liters of distilled water and then reconstituted to buffered saline 0.05 M acetate 0.1 M NaCl pH 4.0. This was applied to a Sephadex (Pharmacia Fine Chemicals, Piscataway, N. J.) G-75 column (1 X 89 cm) and eluted with 0.05 M acetate 0.1 M NaCl pH 4.0 buffer. The fractions collected were tested for the vascular permeability-inducing activity in the skin of rabbits after adjustment to physiological pH and salt concentration.
Sucrose density gradient ultracentrifugation of the permeability-inducing factor(s)
The permeability-inducing protein fractions from the Sephadex G-75 column were pooled, lyophilized, and redissolved in distilled water. The fraction was dialyzed over 90 min against 4 liters of distilled water and then reconstituted to buffered saline 0.15 M NaCl, 0.0175 M phosphate pH 7.4. The concentrated extract was applied to a 10 40% sucrose gradient in buffered saline and centrifuged at 50,000 rpm for 24 hr in a model L Spinco (Beckman Instruments, Inc., Fullerton, Calif.) ultracentrifuge using a SW65 rotor. Molecular weight markers used in these studies included trypsin 23,800 and egg albumin 44,300 (Mann Research Labs., New York). The fractions collected were tested for their vascular permeability-inducing activity in the skin of 550 *ia**~E *T***.:*n;# Histologic changes. Histological changes in the skin site 15 min after the HPAE injection consisted of slight edema of the perivascular tissue with some dilation of the capillaries and venules. In contrast, marked polymorphonuclear infiltration in the tissues was observed in the skin of an animal 21 hr after HPAE injection into an antihistamine pretreated site (Fig. 1) . Thus, the acute permeability effect was characterized by edema and vasodilation without any evidence of polymorphonuclear accumulation while the delayed permeability effect was characterized by leukocytic infiltration.
Duration of the intradermal antihistamine blocking effect. In view of the biphasic permeability-enhancing effect of HPAE, the possibility was considered that the 2-3 hr delayed response in antihistamine pretreated animals represented clearance or inactivation of antihistamine in the skin. ( Table II) . Pretreatment of the skin challenge site with antihistamine for as long as 2 hr before HPAE injection led to inhibition of the acute permeability response.
Duration of activity of HPAE in the skin. The duration of the permeability-enhancing effect of HPAE was also demonstrated by injecting the platelet material at different time intervals before the administration of intravenous Evans blue (Table III) . In these studies the permeability response in the skin was measured 15 min after dye injection. Full permeability-inducing activity II mm, diameter in millimeters of bluing.
was detected at injection sites for up to 2 hr after intradermal injection of permeability factor. When intradermal injection preceded Evans blue administration by more than 2 hr significant diminution of activity was noted.
Effect of platelet extract on rabbit platelet and leukocyte histamine. In order to determine whether the acute permeability effect was due to the action of the HPAE on rabbit platelets, the extract was incubated with washed rabbit platelets in buffer and the supernate tested for the presence of histamine. Histamine was not released from washed platelets in buffer or from platelet rich plasma after incubation with HPAE (Table IV) . For comparison, thrombin released 100% of the histamine present in washed rabbit platelets in buffer, while collagen released 83% of the histamine present in rabbit platelets in plasma. The HPAE also did not release significant amounts of histamine from rabbit exudative polymorphonuclear leukocytes.
Partial purification of the HPAE. Separation of the acid-extracted material on a column of DEAE-cellulose is shown in Fig. 2 . The permeability-inducing activity was localized to the cationic protein fraction which passed through the column without binding. The more anionic platelet proteins including cathepsin A present in peak 4 (10) failed to induce increased vascular permeability upon intradermal injection. Peak 1 of the 552 (Fig. 2) .
The fractions containing permeability-inducing activity obtained from the DEAE column were pooled, concentrated by lyophilization, and applied to a Sephadex G-75 column. The second protein peak obtained from the Sephadex column which had an estimated mol wt of less than 50,000 contained the acute and delayed permeability enhancing activity (Fig. 3) . Cationic gel electrophoresis of this peak revealed 2-3 protein bands.
The fractions containing the permeability-inducing activity obtained from the Sephadex column were pooled, concentrated by lyophilization, and subjected to sucrose density gradient ultracentrifugation. The major protein Fig. 2 . Both permeability-inducing fractions also elicited delayed permeability responses. a column of DEAE-cellulose is shown in Fig. 5A . The acute and delayed permeability-inducing activity was localized to a portion of the cationic protein fraction which passed through the column without binding. The remaining protein fractions had no permeability-enhancing activity. The fractions containing permeabilityinducing activity obtained from the DEAE column were pooled, concentrated by lyophilization, and applied to a Sephadex G-75 column (Fig. 5B) . The second major protein fraction included in the Sephadex column contained the acute and delayed permeability-enhancing activity. Cationic gel electrophoresis of this peak (not shown in Fig. 5 B) revealed two protein bands with similar mobility to the Sephadex column peak of the whole platelet acid extract.
Antiheparin activity and the permeability fractions. The heparin-neutralizing activity of platelets has been attributed to a low molecular weight platelet protein called platelet factor 4 (8) . The antiheparin activity of the HPAE and the partially purified fractions is shown in Table V . The human platelet acid extract demonstrated antiheparin activity similar to that of platelet factor 4 when tested in a thrombin-clotting time system. The DEAE and Sephadex fractions which demonstrated enhanced acute and delayed permeability activity also counteracted the prolongation of the thrombin time produced by heparin.
DISCUSSION
We have demonstrated that a nondialyzable relatively heat-stable human platelet cationic protein fraction of approximate mol wt 30,000 increases vascular permeability in rabbit skin. Our previous studies on platelet granule extract (3) as well as the present purification studies on the granule acid extract strongly suggest that the platelet permeability activity resides in the intracellular granule (presumably lyososomal) fraction.
The most striking feature of the increased permeability effect emphasized by the present studies is the biphasic (acute and delayed) permeability-enhancing response in the rabbit skin. This phenomenon was not demonstrated in the previous permeability studies using mice (3). Our prior permeability studies on rabbits were designed to clarify the nature of the activity and no attempt was made to define an acute versus delayed response (3). Repeated studies using numerous mice which have been pretreated with intraperitoneal antihistamine has revealed complete inhibition of permeability-enhancing effect for as long as 2-3 hr after the intradermal challenge of the platelet acid extract.? Thus it appears that there may be significant species differences in the response to the delayed permeability-enhancing effect of the human platelet permeability factor.
The acute permeability-enhancing effect of the HPAE and of the purified fractions was completely inhibited by prior treatment of the challenged animal by local or parenteral antihistamine. Our previous studies demonstrated that the platelet granule permeability-inducing extract produced degranulation of mouse and rat peritoneal mast cells leading to histamine release (3). There is no evidence from our present studies to suggest that the HPAE caused release of rabbit platelet or rabbit leukocyte intracellular histamine. It thus seems logical to assume that the acute permeability effect in rabbit skin is related to the local accumulation of histamine secondary to tissue mast cell degranulation by the permeability factor. In contrast, the delayed permeability effect in rabbit skin was not inhibited by local or systemic antihistamine administration. The possibility that the delayed response in the antihistamine-treated animal might represent the slow inactivation of antihistamine seems unlikely in view of the findings that the antihistamine effect was demonstrable for as long as 2 hr after intradermal injection (Table III) . The histologic changes in the skin associated with the delayed permeability response were characterized primarily by tissue leukocytosis. chemotaxis, initiated by the platelet permeability factor. It is of interest that Packham, Nishizawa, and Mustard have also previously noted a chemotactic effect of pig platelet permeability factor after injection into rabbit skin (1) . The direct cause of the intradermal delayed response is not evident from our studies; however, it is possible that the cellular exudation with subsequent leukocytic release of lysosomal cationic proteins led to the eventual increase in vascular permeability. Ranadive and Cochrane have demonstrated that three of the isolated cationic rabbit permeability factors can lead to increased vascular permeability independent of histamine release (11) . The question arises whether the biphasic rabbit response is due to one or more individual human platelet permeability factors. We have been unable to separate the acute and delayed permeability effects using the crude platelet acid extract as well as purified fractions. In view of the recently described differentiation of the histamine-dependent and nonhistamine-dependent cationic permeability factors in rabbit exudative neutrophiles, it seems logical to assume that the human platelet histamine-dependent permeability factor may be different from the delayed permeability-enhancing chemotactic factor. Such a differentiation must await further biochemical purification.
It is of interest that the permeability-enhancing fractions also possessed antiheparin activity. Recent studies by Pepper, Moore, and Cash suggest that human platelet antiheparin activity is not homogeneous and may exist in two separate platelet protein fractions (12) . One of these fractions has a high mol wt of approximately 500,000 while the second is apparently a much smaller protein. Pretreatment of rabbits with intradermal heparin did not block the acute or delayed enhanced vascular permeability effects of HPAE.8 It is not clear from our studies whether the antiheparin effect of the platelet permeability-enhancing fraction is due to contamination with one of the forms of platelet factor 4 or to the strongly positive charge of the permeability protein.
Our studies in addition to the earlier findings further substantiate the important role that the platelet may play in inflammatory responses. Recent studies have shown that platelets can synthesize prostaglandin E2 (13), a dialyzable small molecular weight compound (mol wt 350) which increases vascular permeability (14) . Thus the platelet may possess multiple potential mechanisms for influencing inflammatory reactions. It has been well demonstrated over a number of years that early inflammatory changes in injured tissues involve the release of various biologically active materials from leukocyte lysosomes (15) (16) (17) . Included among the ma- 3 Nachman, R., and B. Weksler. Unpublished observations. Sephadex § peak of DEAE fraction + 5
Permeability Activity: The permeability reaction (15 min) was interpreted as present (+) or absent (-). Activity was defined as an intradermal bluing reaction of greater than 8 mm.
The platelet factor 4 assay (antiheparin) was performed as follows: the dotting time was determined in a mixture consisting of 0.3 ml platelet poor plasma, 0.1 ml saline or test reagent, 0.1 ml heparin (0.3 ;/ml) and 0.1 ml thrombin (10 p/ml). All materials were incubated at 370C and all tests performed in duplicate.
* HPAE, human platelet acid extract, protein concentration, 300 pg/ml.
Protein concentration, 340 pg/nil. § Peak B of a Sephadex G-75 separation of the active DEAE peak; protein concentration, 40 pg/ml.
terials are a family of cationic proteins which possess antibacterial activity (18) , enhance vascular permeability (17) , and are pyrogenic (19) . Our studies demonstrate that the circulating platelet may also contribute to the cationic protein mediators of inflammatory responses. In separate experiments it has been demonstrated that bactericidal activity may be induced in human platelets during the active stage of an inflammatory process (20) . In addition, we have recently isolated and characterized a cationic rabbit platelet protein with bactericidal activity (21) . Thus in these respects, the circulating platelet resembles to a significant extent the exudative polymorphonuclear leukocyte. Cotran has previously demonstrated that platelets accumulate in blood vessels adjacent to areas of inflammation and tissue damage (22) . Various inflammatory stimuli including endotoxins, bacteria, circulating immune complexes, as well as endothelial disruption and damage may lead to platelet aggregation and degranulation with release of lysosomal cationic peptides. Platelet aggregates formed in flowing blood have recently been shown to initiate damage in a normal endothelial surface eventually leading to vascular lesions and mural thrombosis (23) . The possibility has to be considered that lysosomal cationic peptide release from aggregated platelets may contribute to these early vascular pathologic abnormalities.
